Arthodar
(Diacerein)Phase 3Small molecule
Diacerein is used to treat osteoarthritis pain and slow down joint damage progression. It helps reduce inflammation and pain in joints affected by osteoarthritis.[1] Arthodar is currently being investigated across 16 indications[3], with its most advanced program in Phase 3.[1]
Arthodar is one of 404 small molecule programs targeting Bullous Pemphigoid. It is currently in Phase 3.
16
Indications
19
Total Trials
3
Active Trials
403
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Arthodar
AANS Pharma
Phase 3
Bnt162b2
BioNTechPreclinical
Biaxin
AbbViePreclinical
Aldactone
PfizerPreclinical
Activella
Eli LillyPreclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Piperacillin/tazobactam
PfizerPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Orap
TevaPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoarthritis5 trials
Diacerein as Adjuvant to Diclofenac Sodium in Indian Patients of Osteoarthritis (OA) Knee
Completed·—·Phase 4·NCT01120015·84 enrolled
Metformin2 trials
9 more indications
Psoriasis Vulgaris1 trial
Topical Diacerein in Psoriasis Vulgaris
Not yet recruiting·—·Phase 4·NCT07352306·60 enrolled
Liver Disease1 trial
Type 2 Diabetes Mellitus1 trial
Inflammatory Cytokines1 trial
Arthritis1 trial
Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
Completed·—··NCT04351100·34 enrolled
Type 2 Diabetes1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diacerein. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AANS Pharma